Company profile
Intra-Cellular Therapies
Neuroscience-focused biopharma (Caplyta/lumateperone), acquired by Johnson & Johnson April 2025 for ~$14.6B
Privately held: no public share price · USA
Assets
(3 total)
3Total Assets
1Approved
0Phase 3 / Filed
2Phase 1–2 / Early
4Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
Lumateperone(Caplyta) | Approved | Serotonin 5-HT2A / dopamine D1-D2 receptorSmall molecule | Major Depressive DisorderSchizophrenia |
| Phase 2 | Dopamine D2/D3 and serotonin 5-HT1A receptorSmall molecule | Alzheimer's Disease | |
| Phase 2 | PDE1Small molecule | Parkinson's Disease |
Upcoming events
Research
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.